See more : Geo Energy Resources Limited (GRYRF) Income Statement Analysis – Financial Results
Complete financial analysis of RVL Pharmaceuticals plc (OSMT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RVL Pharmaceuticals plc, a leading company in the Biotechnology industry within the Healthcare sector.
- The Monks Investment Trust PLC (MNKS.L) Income Statement Analysis – Financial Results
- United Utilities Group PLC (UUGWF) Income Statement Analysis – Financial Results
- Newonder Special Electric Co.,Ltd (301120.SZ) Income Statement Analysis – Financial Results
- IMI plc (IMI.L) Income Statement Analysis – Financial Results
- Executive Network Partnering Corporation (ENPC-UN) Income Statement Analysis – Financial Results
RVL Pharmaceuticals plc (OSMT)
About RVL Pharmaceuticals plc
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 49.72M | 17.50M | 27.76M | 240.03M | 263.70M | 245.75M | 218.46M |
| Cost of Revenue | 9.46M | 3.62M | 3.29M | 111.63M | 140.08M | 125.19M | 125.62M |
| Gross Profit | 40.27M | 13.88M | 24.47M | 128.40M | 123.62M | 120.56M | 92.84M |
| Gross Profit Ratio | 80.98% | 79.33% | 88.14% | 53.49% | 46.88% | 49.06% | 42.50% |
| Research & Development | 3.97M | 6.93M | 13.39M | 32.32M | 43.69M | 42.69M | 29.06M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 81.98M | 87.46M | 72.82M | 93.03M | 74.24M | 56.95M | 65.96M |
| Other Expenses | 6.26M | -1.33M | -48.00K | 884.00K | 664.39K | -4.52M | 168.73K |
| Operating Expenses | 85.95M | 94.39M | 86.21M | 125.35M | 117.94M | 99.64M | 95.02M |
| Cost & Expenses | 95.40M | 98.01M | 89.50M | 236.98M | 258.02M | 224.83M | 220.64M |
| Interest Income | 2.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.11M | 4.02M | 4.10M | 18.21M | 20.79M | 29.05M | 20.19M |
| Depreciation & Amortization | 9.49M | 6.84M | 20.98M | 57.02M | 81.57M | 46.45M | 23.59M |
| EBITDA | -36.19M | -73.67M | -40.76M | 60.95M | -664.39M | 62.85M | 21.58M |
| EBITDA Ratio | -72.78% | -420.94% | -146.83% | 25.39% | 33.34% | 25.57% | 9.88% |
| Operating Income | -45.68M | -80.51M | -61.74M | 3.94M | -98.54M | -52.07M | -32.05M |
| Operating Income Ratio | -91.87% | -460.03% | -222.40% | 1.64% | -37.37% | -21.19% | -14.67% |
| Total Other Income/Expenses | -6.03M | 315.00K | -33.05M | -301.96M | -20.13M | -33.57M | -20.02M |
| Income Before Tax | -51.71M | -82.53M | -94.80M | -298.02M | -118.66M | -85.64M | -52.07M |
| Income Before Tax Ratio | -104.00% | -471.60% | -341.46% | -124.16% | -45.00% | -34.85% | -23.83% |
| Income Tax Expense | -20.00K | 315.00K | -5.78M | -27.12M | -8.98M | -40.49M | -10.25M |
| Net Income | -51.69M | -82.85M | -89.01M | -270.90M | -109.68M | -45.15M | -41.82M |
| Net Income Ratio | -103.96% | -473.40% | -320.63% | -112.86% | -41.59% | -18.37% | -19.14% |
| EPS | -0.58 | -1.23 | -1.47 | -5.17 | -2.42 | -1.05 | -0.98 |
| EPS Diluted | -0.58 | -1.23 | -1.47 | -5.17 | -2.42 | -0.98 | -0.98 |
| Weighted Avg Shares Out | 89.80M | 67.35M | 60.65M | 52.37M | 45.28M | 42.86M | 42.85M |
| Weighted Avg Shares Out (Dil) | 89.80M | 67.35M | 60.65M | 52.37M | 45.28M | 45.86M | 42.85M |
Osmotica Subsidiary RVL Pharmaceuticals, Focused on Eye Care and Ocular Aesthetics, Strengthens and Expands Leadership Team
OSMT Stock Price Increased 33.1%: Why It Happened
Best Penny Stocks on Reddit to Buy Now? 9 That Investors are Bullish On
Osmotica Pharmaceuticals plc Announces Conclusion of Strategic Process with Agreement for the Sale of Legacy Business to Alora Pharmaceuticals, LLC
Osmotica Pharmaceuticals plc Announces Result of Proposal 3 at Annual General Meeting
Osmotica Pharmaceuticals plc to Present at Jefferies Virtual Healthcare Conference 2021
Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q1 2021 Results - Earnings Call Transcript
OSMOTICA PHARM (OSMT) Reports Q1 Loss, Lags Revenue Estimates
Osmotica Pharmaceuticals plc to Present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference
RVL Pharmaceuticals Upneeq® Wins 2021 MedTech Breakthrough Award
Source: https://incomestatements.info
Category: Stock Reports